0 11 Suppression suppression NN 12 14 of of IN 15 32 TNFalpha-mediated tnfalpha-mediated JJ 33 41 NFkappaB NFkappaB NNP 42 50 activity activity NN 51 53 by by IN 54 63 myricetin myricetin NN 64 67 and and CC 68 73 other other JJ 74 84 flavonoids flavonoid NNS 85 92 through through IN 93 107 downregulating downregulate VBG 108 111 the the DT 112 120 activity activity NN 121 123 of of IN 124 127 IKK IKK NNP 128 130 in in IN 131 137 ECV304 ecv304 NN 138 143 cells cell NNS 143 144 . . . 146 156 Flavonoids flavonoid NNS 157 160 are be VBP 161 162 a a DT 163 168 group group NN 169 171 of of IN 172 191 naturally-occurring naturally-occurring JJ 192 200 phenolic phenolic JJ 201 210 compounds compound NNS 211 213 in in IN 214 217 the the DT 218 223 plant plant NN 224 231 kingdom kingdom NN 231 232 , , , 233 236 and and CC 237 241 many many JJ 242 252 flavonoids flavonoid NNS 253 256 are be VBP 257 262 found find VBN 263 267 with with IN 268 276 vascular vascular JJ 277 287 protective protective JJ 288 298 properties property NNS 298 299 . . . 300 312 Nevertheless nevertheless RB 313 316 how how WRB 317 320 the the DT 321 331 protective protective JJ 332 340 response response NN 341 343 is be VBZ 344 351 exerted exert VBN 352 354 by by IN 355 365 flavonoids flavonoid NNS 366 368 is be VBZ 369 372 not not RB 373 377 well well RB 378 391 characterized characterize VBN 391 392 . . . 393 395 In in IN 396 400 view view NN 401 403 of of IN 404 407 the the DT 408 415 nuclear nuclear JJ 416 429 factor-kappaB factor-kappab NN 430 431 ( ( ( 431 439 NFkappaB NFkappaB NNP 439 440 ) ) ) 441 444 may may MD 445 449 play play VB 450 451 a a DT 452 459 central central JJ 460 464 role role NN 465 467 in in IN 468 471 the the DT 472 482 initiation initiation NN 483 485 of of IN 486 501 atherosclerosis atherosclerosis NN 501 502 , , , 503 513 prevention prevention NN 514 516 of of IN 517 520 the the DT 521 531 activation activation NN 532 534 of of IN 535 543 NFkappaB NFkappaB NNP 544 554 represents represent VBZ 555 557 an an DT 558 567 important important JJ 568 572 role role NN 573 575 in in IN 576 586 protecting protect VBG 587 595 vascular vascular JJ 596 602 injury injury NN 602 603 . . . 604 606 In in IN 607 611 this this DT 612 617 study study NN 617 618 , , , 619 622 the the DT 623 630 effects effect NNS 631 633 of of IN 634 644 flavonoids flavonoid NNS 645 647 on on IN 648 673 NFkappaB/inhibitor-kappaB NFkappaB/inhibitor-kappaB NNP 674 675 ( ( ( 675 682 IkappaB IkappaB NNP 682 683 ) ) ) 684 690 system system NN 691 693 in in IN 694 700 ECV304 ecv304 NN 701 706 cells cell NNS 707 716 activated activate VBN 717 721 with with IN 722 727 tumor tumor NN 728 736 necrosis necrosis NN 737 749 factor-alpha factor-alpha NN 750 751 ( ( ( 751 759 TNFalpha TNFalpha NNP 759 760 ) ) ) 761 765 were be VBD 766 774 examined examine VBN 774 775 . . . 776 778 We we PRP 779 791 investigated investigate VBD 792 795 the the DT 796 806 inhibitory inhibitory JJ 807 813 action action NN 814 816 of of IN 817 820 six six CD 821 831 flavonoids flavonoid NNS 832 834 on on IN 835 842 IkappaB IkappaB NNP 843 849 kinase kinase NNP 850 851 ( ( ( 851 854 IKK IKK NNP 854 855 ) ) ) 856 864 activity activity NN 864 865 , , , 866 868 an an DT 869 875 enzyme enzyme NN 876 884 recently recently RB 885 890 found find VBD 891 893 to to TO 894 907 phosphorylate phosphorylate VB 908 916 critical critical JJ 917 923 serine serine NN 924 932 residues residue NNS 933 935 of of IN 936 943 IkappaB IkappaB NNP 944 947 for for IN 948 959 degradation degradation NN 959 960 . . . 961 963 Of of IN 964 967 six six CD 968 978 flavonoids flavonoid NNS 979 985 tested test VBN 985 986 , , , 987 996 myricetin myricetin NN 997 1000 was be VBD 1001 1006 found find VBN 1007 1009 to to TO 1010 1018 strongly strongly RB 1019 1026 inhibit inhibit VB 1027 1030 IKK IKK NNP 1031 1037 kinase kinase NNP 1038 1046 activity activity NN 1046 1047 , , , 1048 1051 and and CC 1052 1059 prevent prevent VBP 1060 1063 the the DT 1064 1075 degradation degradation NN 1076 1078 of of IN 1079 1091 IkappaBalpha IkappaBalpha NNP 1092 1095 and and CC 1096 1107 IkappaBbeta IkappaBbeta NNP 1108 1110 in in IN 1111 1120 activated activate VBN 1121 1132 endothelial endothelial JJ 1133 1138 cells cell NNS 1138 1139 . . . 1140 1151 Furthermore furthermore RB 1151 1152 , , , 1153 1162 myricetin myricetin NN 1163 1166 was be VBD 1167 1171 also also RB 1172 1177 found find VBN 1178 1180 to to TO 1181 1188 inhibit inhibit VB 1189 1197 NFkappaB NFkappaB NNP 1198 1206 activity activity NN 1207 1217 correlated correlate VBD 1218 1222 with with IN 1223 1234 suppression suppression NN 1235 1237 of of IN 1238 1246 monocyte monocyte NN 1247 1255 adhesion adhesion NN 1256 1258 to to TO 1259 1265 ECV304 ecv304 NN 1266 1271 cells cell NNS 1271 1272 . . . 1273 1282 Therefore therefore RB 1283 1285 we we PRP 1286 1294 conclude conclude VBP 1295 1299 that that IN 1300 1310 flavonoids flavonoid NNS 1311 1314 may may MD 1315 1317 be be VB 1318 1320 of of IN 1321 1332 therapeutic therapeutic JJ 1333 1338 value value NN 1339 1342 for for IN 1343 1351 vascular vascular JJ 1352 1359 disease disease NN 1360 1367 through through IN 1368 1372 down down JJ 1373 1383 regulation regulation NN 1384 1386 of of IN 1387 1403 NFkappaB/IkappaB NFkappaB/IkappaB NNP 1404 1410 system system NN 1410 1411 . . . 1412 1421 Copyright Copyright NNP 1422 1426 1999 1999 CD 1427 1437 Wiley-Liss Wiley-Liss NNP 1437 1438 , , , 1439 1442 Inc Inc NNP 1442 1443 . . .